Hap Trading, LLC Bei Gene, Ltd. Transaction History

Hap Trading, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $1.43 Million - $2.61 Million	11,398 New	11,398 $2.51 Million
Q2 2022 Aug 12, 2022	BUY	$121.11 - $216.05 $1.22 Million - $2.18 Million	10,091 Added 90.49%	21,243 $3.44 Million
Q1 2022 May 12, 2022	SELL	$146.52 - $269.56 $89,230 - $164,162	-609 Reduced 5.18%	11,152 $2.1 Million
Q3 2019 Nov 12, 2019	BUY	$120.61 - $148.29 $1.42 Million - $1.74 Million	11,761 New	11,761 $1.44 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.